Physician conformity and patient adherence to ACE inhibitors and ARBs in patients with diabetes, with and without renal disease and hypertension, in a medicaid managed care organization

Journal of Managed Care Pharmacy

Volumn 12, Issue 8, 2006, Pages 649-655

  Cooke, Catherine E ^a,b,d   Fatodu, Hugh ^c  

^a PFIZER INC   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF PHARMACY   (United States)

^c JOHNS HOPKINS UNIVERSITY   (United States)

^d NONE   (United States)

Author keywords

Adherence; Angiotensin receptor blocker (ARB); Angiotensin converting enzyme (ACE) inhibitor; Diabetes mellitus; Hypertension

Indexed keywords

AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; BENAZEPRIL; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; FOSINOPRIL; HYDROCHLOROTHIAZIDE; IRBESARTAN; LISINOPRIL; LOSARTAN; QUINAPRIL; RAMIPRIL; TRANDOLAPRIL; VALSARTAN; VERAPAMIL;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BILLING AND CLAIMS; CONTROLLED STUDY; DIABETIC HYPERTENSION; DIABETIC NEPHROPATHY; FEMALE; HEALTH CARE ORGANIZATION; HEALTH CARE UTILIZATION; HEALTH INSURANCE; HUMAN; INTERNATIONAL CLASSIFICATION OF DISEASES; MAJOR CLINICAL STUDY; MALE; MEDICAID; MEDICAL PRACTICE; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT COMPLIANCE; PHYSICIAN ATTITUDE; PRACTICE GUIDELINE; PROTEINURIA; CHRONIC KIDNEY FAILURE; CLINICAL PRACTICE; COHORT ANALYSIS; COMORBIDITY; DIABETES MELLITUS; HEALTH MAINTENANCE ORGANIZATION; HYPERTENSION; MIDDLE AGED; ORGANIZATION AND MANAGEMENT; STANDARD; UNITED STATES;

ADULT; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; COHORT STUDIES; COMORBIDITY; DIABETES MELLITUS; FEMALE; HEALTH MAINTENANCE ORGANIZATIONS; HUMANS; HYPERTENSION; KIDNEY FAILURE, CHRONIC; MALE; MARYLAND; MEDICAID; MIDDLE AGED; PATIENT COMPLIANCE; PHYSICIAN'S PRACTICE PATTERNS;

EID: 33847300618     PISSN: 10834087     EISSN: None     Source Type: Journal    
DOI: 10.18553/jmcp.2006.12.8.649     Document Type: Article

References (17)

1. Centers for Disease Control and Prevention. National diabetes fact sheet: general information and national estimates on diabetes in the United States, 2002. Atlanta, GA: Centers for Disease Control and Prevention; 2003.
2. American Diabetes Association. Treatment of hypertension in adults with diabetes. Diabetes Care. 2002;25(suppl 1):S71-S73.
3. American Diabetes Association. Hypertension management in adults with diabetes. Diabetes Care. 2004;(suppl 1):S65-S67.
4. Adler AI, Stratton IM, Neil HAW, et al. on behalf of the United Kingdom Prospective Diabetes Study Group. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes: UKPDS 36. BMJ. 2000;321:412-19.
5. United Kingdom Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. BMJ. 1998;317:713-20.
6. U.S. Department of Health and Human Services, National Institutes of Health. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Bethesda, MD: National Institutes of Health; 2004. NIH publication no. 04-5230.
7. Teo KK, Mitchell LB, Pogue J, Bosch J, Dagenais G, Yusuf S, on behalf of the HOPE investigators. Effect of ramipril in reducing sudden deaths and nonfatal cardiac arrests in high-risk individuals without heart failure or left ventricular dysfunction. Circulation. 2004;110:1413-17.
8. Mann JFE, Gerstein HC, Pogue J, Bosch J, Yusuf S, for the HOPE investigators. Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial. Ann Intern Med. 2001;134:629-36.
9. American Diabetes Association. Diabetic nephropathy. Diabetes Care. 2002;25(suppl 1):S85-S89.
10. American Diabetes Association. Nephropathy in diabetes. Diabetes Care. 2004;27(suppl 1):S79-S83.
11. Malini PL, Strocchi E, Fiumi N, Ambrosioni E, and Ciavarella A. ACE inhibitor-induced cough in hypertensive type 2 diabetic patients. Diabetes Care. 1999;22:1586-87.
12. Timpe EM, Amarshi N, Reed PJ. Evaluation of angiotensin-converting enzyme inhibitor use in patients with type 2 diabetes in a State managed care plan. Am J Manag Care. 2004;10:124-29.
13. Al Khaja KAJ, Sequeira RP, Mathur VS, Damanhori AHH, Wahab AWMA. Family physicians' and general practitioners' approaches to drug management of diabetic hypertension in primary care. J Eval Clin Pract. 2002;8:19-30.
14. Andros V, Egger A, Dua U. Blood pressure goal attainment according to JNC 7 guidelines and utilization of antihypertensive drug therapy in MCO patients with type 1 or type 2 diabetes. J Manag Care Pharm. 2006;12(4):303-09. Available at: http://www.amcp.org/data/jmcp/May06_Journal.pdf. Accessed October 10, 2006.
15. Strippoli GFM, Craig M, Craig JC. Antihypertensive agents for preventing diabetic kidney disease. Cochrane Database of Systematic Reviews. 2005, issue 4. Art no.: CD004136.DO1:10.1002/14651858.CD004136.pub2.
16. Wannemacher AJ, Schepers GP, Townsend KA. Antihypertensive medication compliance in a Veterans Affairs healthcare system. Ann Pharmacother. 2002;36:986-91.
17. Grant RW, Devita NG, Singer DE, Meigs JB. Polypharmacy and medication adherence in patients with type 2 diabetes. Diabetes Care. 2003;26:1408-12.